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Abstract
Patients diagnosed with polycystic ovary syndrome (PCOS) are at high risk of developing a
myriad of endocrinologic and metabolic derailments. Moreover, PCOS is a leading cause of
habitual abortion, also known as recurrent pregnancy loss (RPL). Meteorin-like protein
(Metrnl) is a newly discovered adipokine with the potential to counteract the metaflamma-
tion. This study aimed at determining the associations of serum Metrnl levels with homocys-
teine, hs-CRP, and some components of metabolic syndrome in PCOS-RPL and infertile
PCOS patients.This case-control study was conducted in 120 PCOS patients (60 PCOS-
RPL and 60 infertile) and 60 control. Serum hs-CRP and homocysteine were assessed
using commercial kits, while adiponectin, Metrnl, FSH, LH, free testosterone and insulin lev-
els were analyzed using ELISA technique. Serum Metrnl levels were found to be lower in
PCOS patients when compared to controls (67.98 ± 26.66 vs. 96.47 ± 28.72 pg/mL, P
<0.001)). Furthermore, serum adiponectin levels were lower, while free testosterone, fasting
insulin, HOMA-IR, homocysteine, and hs-CRP were significantly higher in PCOS group
compared to controls. Moreover, serum Metrnl correlated with BMI, adiponectin, and homo-
cysteine in controls, and inversely correlated with FBG, fasting insulin, and HOMA-IR in
PCOS group and subgroups. Besides, it inversely correlated with hs-CRP in control, and
PCOS group and subgroups. These findings revealed a possible role of Metrnl in the patho-
genesis of PCOS and RPL. Nevertheless, there is a necessity for future studies to prove this
concept.
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Introduction
Infertility, or the inability to conceive for more than twelve months, is a highly prevalent repro-
ductive problem, affecting 8–12% of reproductive-aged couples globally [1]. More than 50% of
the cases are related to male gender irregularities; however, infertility continues to be a female’s
social burden [2].
Polycystic ovary syndrome (PCOS) is one of the most prevalent ovulatory disorders con-
tributing to infertility. It is a common polygenic, multifactorial, inflammatory, endocrine
disorder, which evinces mainly due to lifestyle factors such as low-fiber high-fat diet, sedentary
lifestyle, smoking and alcohol consumption [3–7], with a global prevalence of about 20% of
women of reproductive age [8]. It is characterized by disrupted neuroendocrine mechanisms
and a vast degree of symptomatic heterogeneity in ovulatory dysfunction, functional hyper-
androgenism, and polycystic ovary morphology (PCOM) [9]. Females affected by PCOS may
suffer from fertility challenges, oblivious to their ovulatory disorder until they become diag-
nosed with habitual abortion, also known as recurrent pregnancy loss (RPL)–defined as at
least two consecutive abortions within the first 20 weeks of pregnancy, with an incidence of
1in 300 pregnancies [10]. The pathogenesis of PCOS shares several features with metabolic
syndrome (MetS), including dysfunctional adipose tissue with visceral adiposity, impaired
insulin action with an increased risk for developing type II diabetes mellitus (T2DM), pro-
atherogenic dyslipidemia, non-alcoholic fatty liver disease (NAFLD), and metaflammation
[11–14].
Adipose tissue is not a mere fat depot; it is a metabolically active organ, releasing several
cytokines, known as adipokines, regulating metabolic homeostasis and immune response. As a
result of excess energy balance, the tissue cell mass expands. Metabolic dysregulation occurs
whenever the expansion rate exceeds vascularization status. A sequela of impaired angiogene-
sis, hypoxia, cell death, and fibrosis take place, attracting macrophages and other immune
cells, with an upregulation of pro-inflammatory (tumor necrosis factor (TNF)-α, Interleukin
(IL)-6) and pro-fibrogenic factors (collagen and lysyl oxidase (LOX)). This eventually leads to
a state of metaflammation [15, 16], and dysregulated release of adipokines, coercing mesen-
chymal stem cells to commit to the adipocyte lineage [17]. This pathology is the link between
excess adiposity and number of disorders, including osteosarcopenic obesity [18], insulin
resistance, T2DM [19], tumors [20], etc. Ongoing research revealed that adipocyte dysfunction
is pivotal in the pathogenesis of ovulatory disorders in females [21], including PCOS [22].
Meteorin-like protein (Metrnl) is a novel immunoregulatory adipokine, widely expressed
by white adipocytes, activated monocytes and macrophages [23, 24]. It promotes the differen-
tiation of functional adipocytes and the browning of white adipocytes upon thermogenic stim-
ulus, antagonizes insulin resistance, and suppresses inflammatory immune response [25].
Few studies have investigated Metrnl in the clinical setting [24, 26–28]. Much of the infor-
mation is derived from animal studies, and none of them considered a possible relation
between Metrnl and MetS within the pathogenesis of PCOS. The focus of this study is to inves-
tigate a possible association between Metrnl with components of MetS and cardiovascular bio-
markers, and its relation with the pathogenesis of PCOS and RPL.
Materials and methods
Study design, setting, and participants
The study was conducted under the Declaration of Helsinki and was approved by the Ethical
Committee of Tehran University of Medical Sciences, Tehran, Iran. All enrolled subjects
signed a written consent form. Subjects were selected from the Obstetrics and Gynecology
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Department of Ibn Sina Infertility Center, Tehran, Iran, and controls were recruited from
those performing routine checkups in the laboratory at the same center, from May 2017 to Jan
2018. The subjects were previously involved in our studies on PCOS and adipokines, and some
of their data have been utilized in a recent publication [29].
This case-control study included 60 PCOS-RPL, 60 infertile PCOS (PCOS-Inf) and 60 con-
trol aged between 20–40 years, as described previously (published data) [29]. The inclusion cri-
terion included PCOS diagnosis according to the 2003 Rotterdam Criteria [30], which dictates
that two out of the following three characteristics should be met, PCOM on ultrasound, clinical
and/or biochemical hyperandrogenism, and oligo- or ano-vulation (oligo-amenorrhea), with
differential diagnosis of conditions such as hyperprolactinemia, thyroid diseases, premature
ovarian failure, congenital adrenal hyperplasia, Cushing’s syndrome, and adrenal tumors.
PCOM was defined as presence of at least 12 follicles with a diameter of 2–9 mm in each ovary
and/or increased ovarian volume (at least 10 mm 3), detected by sonographic imaging. Hyper-
androgenism was defined as clinical symptoms (hirsutism with modified Ferriman-Gallwey
score exceeding 8) and/or biochemical symptoms with an increment in serum free testoster-
one levels (exceeding 0.6 pg/mL) [30, 31]. Chronic oligo- and/or amenorrhea (oligo- or anovu-
lation) were defined as infrequent menstruation with menstrual cycle exceeding 35 days, with
less than eight cycles per year. Subjects designated for the PCOS-RPL group were those who
simultaneously had at least two consecutive miscarriages before their 20th week of gestation
[32]. Infertile patients were those who were unable to conceive after one year of unprotected
intercourse as a consequence of PCOS pathogenesis. Complete evaluation of all PCOS subjects
were performed. Females with other causes of infertility such as tubal factor infertility, endo-
metriosis, and anatomical abnormalities in the reproductive tract were excluded. The control
group included fertile subjects with regular menstrual cycles and had no clinical/biochemical
hyperandrogenism. Subjects who smoke, are pregnant, are lactating, have gynecological or
obstetric problems, are receiving hormonal therapy, have viral, bacterial, or inflammatory dis-
ease, or suffer from CVD, thyroid diseases, or DM were excluded. Moreover, subjects who
have been taking the following pharmaceutical products for the past six months were excluded:
glucocorticoids, prescription weight loss drugs, estrogenic and anti-androgenic drugs, and
anti-hypertensive drugs.
Variable measurements
Anthropometrics and biochemical measurements. Anthropometric data, lifestyle fac-
tors, and medications were obtained for each subject. BMI was calculated using a standard for-
mula [weight (kg)/ height (m2)]. Five milliliters of venous blood were collected from each
subject after overnight fasting at the follicular phase of their menstrual cycle. FBG, lipid profile
(serum triglyceride (TG), total cholesterol (TC), LDL-C, HDL-C), homocysteine, hs-CRP, fast-
ing insulin, free testosterone, FSH, and LH were measured as previously described [29]. The
homeostatic model assessment of insulin resistance (HOMA-IR) was calculated using the fol-
lowing equation: [(FBG (mg/dL)] × [fasting blood insulin (μU/mL)] / 405 [33].
Measuring adipokines. Serum levels of adiponectin were measured using ELISA tech-
nique, as previously described [29]. Commercial ELISA kits were utilized to measure serum
levels of Metrnl protein (Aviscera Biosciences, U.S.A.). Moreover, the intra- and inter-assay
coefficients of variation (CV) of Metrnl were 5% and 4.67%, respectively.
Bias
Selection bias was addressed by closely matching cases to controls based on age and BMI.
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Statistical methods and sample size calculation
Statistical analysis was performed using IBM SPSS Statistics 20.0 (IBM SPSS, Chicago, IL, U.S.
A.). Categorical variables were presented in frequency and percentage, and compared by Chi-
square test. The normality of the continuous variables was checked using Kolmogorov-Smir-
nov test. Normal variables were presented by mean and standard deviation (SD) and com-
pared using Student’s T test or one-way ANOVA with Bonferroni test. Skewed data were
represented as median and quartile ranges, and compared using Mann-Whitney U test or
Kruskal-Wallis tests, with Bonferroni corrections post hoc test. The effect of confounders (age,
BMI, adiponectin levels, and metformin administration) on serum Metrnl was adjusted using
Analysis of covariance (ANCOVA). Before heading toward further analysis, the logarithms of
nonparametric data were calculated to approximate normality. The correlation between serum
Metrnl with anthropometric and metabolic variables was tested using Pearson correlation test.
Multiple linear regression was performed with all correlated parameters with serum Metrnl.
The association of serum Metrnl with the risk of PCOS and RPL was assessed by multinomial
logistic regression. All tests were two-sided, and a p-value of less than 0.05 was considered of
statistical significance.
The sample size was determined on the basis of obtaining a significant difference of serum
Metrnl level between two groups of 15 pg/mL, with an estimated SD of 23 pg/mL in each
group, 95% statistical power, and 5% type I error [34].
Results
Characteristics of the study population
Table 1 lists the characteristics of the study population. When comparing controls to the
PCOS group, there was no significant difference in terms of age, BMI, FBG, TG, TC, LDL-C,
HDL-C, LH, FSH, and LH to FSH ratio levels. However, the PCOS group, compared to con-
trols, had significantly higher levels of free testosterone, fasting insulin, and HOMA-IR.
Furthermore, PCOS-Inf, PCOS-RPL, and control subjects were similar in terms of age,
BMI, TC, LDL-C, and HDL-C. However, serum TG was significantly higher in PCOS-RPL
than in infertile PCOS patients. Concerning the hormonal profile, PCOS-Inf subgroup had
higher LH to FSH ratio and free testosterone levels, when compared to PCOS-RPL subgroup.
Despite similar serum levels of FBG, PCOS-Inf and PCOS-RPL subgroups had significantly
higher levels of fasting insulin and HOMA-IR, when compared to the control group, with
higher levels in the infertile subgroup. These findings were similar to those in our previous
publication [29].
The whole sample was stratified according to BMI stages: normal weight (BMI < 25 Kg/
m2) and overweight/obese (BMI� 25 Kg/m2) for further analysis. Overweight/obese subjects
exhibited significantly lower levels of serum HDL-C in the PCOS-RPL subgroup, lower levels
of FSH in the PCOS group and infertile subgroup, and higher levels of fasting insulin in the
PCOS group and PCOS-inf subgroup, when compared to their normal-weight counterparts
(P< 0.05 for all). Moreover, they had significantly lower levels of serum adiponectin in all
groups (P< 0.05), except for the PCOS-RPL subgroup, although not statistically significant.
(S1 Table)
Serum levels of cardiovascular biomarkers and adipokines
The serum levels of homocysteine were significantly higher in the PCOS group and PCOS-RPL
subgroup when compared to control. Furthermore, serum hs-CRP levels were significantly
higher in the PCOS group and subgroups, when compared to the control group. (Fig 1)
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On the other hand, serum adiponectin levels were significantly lower in the PCOS group
and subgroups, when compared to controls. These results were similar to those we have pub-
lished previously [29]. Likewise, serum levels of Metrnl were significantly lower in PCOS
group (67.98 ± 26.66 pg/mL), PCOS-Inf (66.57 ± 28.14 pg/mL) and PCOS-RPL subgroups
(69.39 ± 25.25 pg/mL), when compared to controls (96.47 ± 28.72 pg/mL) (P < 0.001 for all)
(Fig 2). Following adjustment for the covariates (age, BMI, serum adiponectin, and metfor-
min), the difference remained significant in serum Metrnl levels between control and PCOS
groups (P< 0.001). It is noteworthy to point that no significant difference was observed in the
levels of the three variables among the PCOS subgroups.
The difference in serum Metrnl protein between the groups was further tested after stratifi-
cation by BMI, into normal weight (BMI < 25 Kg/m2) against overweight/obese (BMI� 25
Kg/m2) (Table 2). Serum Metrnl levels showed no significant difference between overweight/
obese individuals than normal-weight in the control group, PCOS-Inf and PCOS-RPL groups.
Intriguingly, overweight/obese subjects demonstrated lower Metrnl levels compared to normal
weight subjects in whole sample and PCOS groups.
Association of serum Metrnl with clinical parameters
Correlations between serum Metrnl level and other clinical parameters were analyzed
(Table 3). Serum Metrnl levels inversely correlated with BMI and circulating LH levels in the
Table 1. Clinical features of the study pulation.
Variables Control group (n = 60) PCOS group (n = 120) PCOS-Inf subgroup (n = 60) PCOS-RPL subgroup (n = 60) p-value
Age (years) 30.02 ± 4.60 29.88 ± 4.22 29.88 ± 4.23 29.88 ± 4.23 0.981
BMI (Kg/m2) 25.48 ± 3.26 26.01 ± 3.39 25.86 ± 3.53 26.17 ± 3.25 0.536
FBG (mg/dL) 91.15 ± 9.68 90.62 ± 10.76 90.92 ± 11.6 90.32 ± 9.95 0.903
TG (mg/dL) 122.5 [97.5–155.0] 126.5 [92.5–165.5] 111.5 [82.5–142.0] 145.0 [103.25–175.25] d�� 0.009
TC (mg/dL) 163.84 ± 39.09 173.61 ± 35.58 171.82 ± 33.70 175.40 ± 37.57 0.216
LDL-C (mg/dL) 96.80 ± 30.21 100.84 ± 29.26 102.48 ± 26.81 99.20 ± 31.66 0.575
HDL-C (mg/dL) 46.09 ± 6.91 45.00 ± 9.93 44.93 ± 8.69 45.06 ± 11.11 0.744
FSH (IU/L) 6.43 ± 2.40 7.00 ± 3.30 7.00 ± 4.02 7.00 ± 2.40 0.500
LH (IU/L) 8.56 ± 2.38 9.38 ± 5.01 10.08 ± 3.95 8.68 ± 5.84 0.099
Free Testosterone (pg/mL) 1.50 ± 0.34 3.19 ± 1.10 a�� 3.15 ± 0.90 b�� 3.24 ± 1.28 c�� < 0.001
Log LH to FSH ratio 1.29 [0.96–1.92] 1.26 [0.92–1.90] 0.40 [0.10–0.70] 0.08 [-0.34–0.54] d�� 0.009
Fasting Insulin (μU/mL) 2.94 [2.12–4.16] 3.71 [2.61–6.43] a� 3.77 [2.93–5.37] b� 3.32 [2.20–7.34] c� 0.008
HOMA-IR 0.62 [0.45–0.97] 0.78 [0.61–1.33] � 0.80 [0.61–1.24] b� 0.74 [0.53–1.76] c� 0.012
Metformin (%) 1 (1.5) 66 (65.3) 28 (41.8) 38 (56.7) < 0.001
Categorical data are given in frequency and percentage
Parametric data are given as mean ± standard deviation
Non-parametric data are given as median and interquartile range [25–75%]
Post Hoc Analysis are given as mean and median of each group on the far-right column
a Comparison between Control group and PCOS group
b Comparison between Control group vs PCOS-inf subgroup
c Comparison between Control group and PCOS-RPL subgroup
d Comparison between PCOS-inf and PCOS-RPL subgroups
� P < 0.05 is of statistical significance
�� P < 0.001 is of statistical significance
PCOS: Polycystic ovary syndrome; RPL: Recurrent pregnancy loss; PCOS-inf: infertile PCOS; BMI: Body mass index; FBG: fasting blood glucose; TG: triglyceride; TC:
total cholesterol; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; LH: luteinizing hormone; FSH: follicle-stimulating
hormone; HOMA-IR: Homoeostasis Model Assessment of Insulin Resistance
https://doi.org/10.1371/journal.pone.0231943.t001
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control group and PCOS-RPL group. In the PCOS group and subgroups, it negatively associ-
ated with the parameters of glucose homeostasis: FBG, log fasting insulin, and log HOMA-IR.
No associations were detected between serum Metrnl levels and age, serum levels of TC,
LDL-C, HDL-C, LH, and FSH, and LH to FSH ratio in PCOS subgroups.
Furthermore, a positive correlation was noted with log serum adiponectin in the control
group only. On the other hand, an inverse correlation existed between serum Metrnl and hs-
CRP levels in all groups, but with a higher statistical significance in the PCOS group and sub-
groups, as compared to controls. However, an inverse correlation between serum Metrnl and
homocysteine was observed only in the whole sample (r = - 0.153, P = 0.040), which remained
valid even after adjustment for folic acid intake (P = 0.039).
Next, multiple linear regression models were used to validate the prediction of serum Metrnl
protein with those variables that had previously showed significant correlations. A multiple regres-
sion was operated to predict serum Metrnl levels from BMI, FSH, hs-CRP and log serum adipo-
nectin in the control group. BMI (- 0.268, 95% CI [- 4.52—- 0.20]), serum hs-CRP (-0.260, 95%
CI [- 15.24—- 0.72]) and LH (- 0.347, 95% CI [- 6.98—- 1.40]) significantly predicted serum
Metrnl (P< 0.05). In PCOS group, FBG (1.965, 95% CI [0.70–9.04]), log fasting insulin (10.650,
95% CI [96.89–855.06]), log HOMA-IR (- 11.598, 95% CI [- 866.33—- 106.15]) and serum hs-
CRP (- 0.321, 95% CI [- 10.09—- 3.24]) significantly predicted serum Metrnl (P< 0.05). Serum
hs-CRP (- 0.328, 95% CI [- 13.25—- 1.71]) and log serum adiponectin (- 0.328, 95% CI [- 38.05—
- 5.49]) significantly predicted serum Metrnl in the PCOS-Inf subgroup (P< 0.05). Finally, in the
Fig 1. Serum levels of cardiovascular biomarkers and adiponectin. (a) Comparison of serum levels of homocysteine (μmol/L) in
control vs. PCOS group (P < 0.05), and (b) control vs. PCOS-Inf vs. PCOS-RPL subgroups (P < 0.05). (c) Comparison of serum levels
of hs-CRP (mg/L) in control vs. PCOS group (P< 0.05), and (d) control vs. PCOS-Inf vs. PCOS-RPL subgroups (P< 0.001). (e)
Comparison of serum levels of adiponectin (μmol/L) in control vs. PCOS group (P< 0.001), and (f) control vs. PCOS-Inf vs.
PCOS-RPL subgroups (P< 0.001). PCOS: Polycystic ovary syndrome; PCOS-Inf: Infertile PCOS; RPL: Recurrent pregnancy loss; hs-CRP:
high sensitivity C-reactive protein.
https://doi.org/10.1371/journal.pone.0231943.g001
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PCOS-RPL, serum hs-CRP (- 0.291, 95% CI [- 10.09—- 0.89]) and log serum HOMA-IR (- 0.243,
95% CI [- 17.36—- 0.03]) significantly predicted serum Metrnl (P< 0.05).
Discussion
Obesity and adipose tissue dysfunction, as a part of MetS, are common in patients diagnosed
with PCOS, adversely affecting their cardiometabolic function and systemic homeostasis
Fig 2. Serum levels of Metrnl protein (pg/mL) in control vs. infertile PCOS vs. PCOS-RPL subgroups
(96.47 ± 28.72, 66.57 ± 28.14, and 69.39 ± 25.25, respectively, P< 0.001). PCOS: Polycystic ovary syndrome;
PCOS-Inf: Infertile PCOS; RPL: Recurrent pregnancy loss.
https://doi.org/10.1371/journal.pone.0231943.g002
Table 2. Mean comparison of serum Metrnl levels in normal (< 25kg/m2) and overweight/obese (� 25 kg/m2) patients.
Groups BMI Staging Number of Cases Metrnl (pg/mL) p-value
Whole Sample (n = 180) Normal Weight 79 82.19 ± 31.89 0.008
Overweight/Obese 101 742.21 ± 28.28
Control group (n = 60) Normal Weight 26 103.87 ± 27.78 0.080
Overweight/Obese 34 90.80 ± 28.52
PCOS group (n = 120) Normal Weight 53 74.54 ± 29.43 0.019
Overweight/Obese 67 62.79 ± 23.17
PCOS-Inf subgroup (n = 60) Normal Weight 27 72.35± 30.45 0.152
Overweight/Obese 33 61.84 ± 25.59
PCOS-RPL subgroup (n = 60) Normal Weight 26 76.82 ± 28.75 0.056
Overweight/Obese 34 63.70 ± 20.90
The data are represented as mean ± standard deviation (SD).
PCOS: Polycystic ovary syndrome; PCOS-Inf: Infertile PCOS; RPL: Recurrent pregnancy loss; BMI: Body mass index
https://doi.org/10.1371/journal.pone.0231943.t002
PLOS ONE Circulating Metrnl protein in polycystic ovary syndrome
PLOS ONE | https://doi.org/10.1371/journal.pone.0231943 April 24, 2020 7 / 15
through a disrupted release of adipokines. Intriguingly, insulin resistance has a bidirectional
relationship with adipocyte dysfunction, and is an essential contributing factor in the trigger
and exacerbation of PCOS pathogenesis. This study is the first to show that serum levels of
Metrnl tend to be lower in patients diagnosed with PCOS and RPL, inversely correlating with
markers of glucose homeostasis and inflammation.
The low serum levels of Metrnl in patients diagnosed with PCOS showed an independent
association with the pathogenesis of the disease, partly through insulin resistance, as evidenced
by the correlation between Metrnl levels and glucose homeostasis parameters. Similar correla-
tion was observed in several studies [35–37]. For instance, Wang et al. found that Metrnl levels
positively correlated with FBG, post-prandial BG, HbA1c, fasting insulin, and HOMA-IR. The
authors regarded that Metrnl elevated the risk of T2DM, independent of insulin resistance
[38]. Moreover, experimental studies have shown that Metrnl knockout models developed
insulin resistance in response to high-fat diet (HFD); on the contrary, Metrnl overexpression
in transgenic mice were able to antagonize it [28, 39]. A recent study by Lee et al. found that
Metrnl improved glucose tolerance by increasing the phosphorylation of histone deacetylase 5
(HDAC5), thereby activating GLUT4 transcription, in an AMPKα2-dependent pathway, in
HFD-induced obese or diabetic mice [34]. However, the methodology of the present study
limits a causal relationship between lower levels of serum Metrnl and insulin resistance in
PCOS setting. Nevertheless, it can be interpreted that these levels reflect the metabolic impair-
ments observed in these patients.
Moreover, our results showed a significant decrement in serum Metrnl levels in over-
weight/obese individuals regardless of their disease status, when compared to controls [40, 41].
Lowest levels were observed in infertile obese patients diagnosed with PCOS. However, the
association of serum Metrnl with obesity biomarkers is still paradoxical. For instance, El-Ash-
mawy et al. and other authors found no association between serum Metrnl and BMI [28, 42,
43]; while Al-Khairi at el. found a significant correlation between the two in obese subjects
[37]. This paradox might be due to methodological differences in terms of obesity cutoffs, i.e.
BMI exceeding 25 Kg/m2 or 30 Kg/m2. Nevertheless, stratifying individuals according to BMI
alone has been regarded as “an imperfect predictor of body composition and disease risk, but
still has some clinical value as a crude estimate”, posing the risk of misclassification [44]. For
Table 3. Correlation of serum Metrnl protein with anthropometric, hormonal and biochemical variables.
Variables Control group (n = 60) PCOS group (n = 120) PCOS-Inf subgroup (n = 60) PCOS-RPL subgroup (n = 60)
BMI (Kg/m2) - 0.347�� - 0.138 - 0.011 - 0.297�
FBG (mg/dL) - 0.230 - 0.314�� - 0.318� - 0.306�
Log TG 0.017 - 0.118 - 0.270� 0.015
LH (IU/L) - 0.277� 0.086 0.072 0.117
Log Fasting Insulin - 0.174 - 0.248�� - 0.278� - 0.236
Log HOMA-IR - 0.199 - 0.293�� - 0.319� - 0.281�
hs-CRP (mg/L) -0.283� -0.365�� -0.364�� - 0.365��
Homocysteine (μmol/L) - 0.214 - 0.028 - 0.012 - 0.043
Log Adiponectin 0.323� - 0.012 - 0.124 0.086
Pearson correlation analyses were performed to determine if an association exists between the variables.
� P < 0.05
�� P < 0.01
PCOS: Polycystic ovary syndrome; PCOS-Inf: Infertile PCOS; RPL: Recurrent pregnancy loss; BMI: Body mass index; FBG: fasting blood glucose; TG: triglyceride; LH:
luteinizing hormone; HOMA-IR: Homoeostasis Model Assessment of Insulin Resistance; hs-CRP: high sensitivity C-reactive protein
https://doi.org/10.1371/journal.pone.0231943.t003
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instance, Stefanaki et al. showed that lean PCOS females (BMI 18.5–24.9 kg/m2) exhibited an
osteosarcopenic phenotype, characterized by low muscle mass and bone mineral density, but
normal total and subcutaneous fat mass [45]. A recent study by Du et al. found that serum
Metrnl levels negatively correlated with visceral adiposity (exceeding 100 cm2) in diabetic
patients (OR = 0.846, 95% CI [0.745–0.961], P = 0.01) [46]. Therefore, there is a need to assess
the functional body composition of PCOS subjects to have a better image on the association of
fat mass and fat free mass with, in this case, serum Metrnl levels. In addition, physical activity
could be a confounding factor, elevating the levels of Metrnl in obese and/or diabetic patients
in these studies. Exercise training induces mitochondrial biogenesis and release of Metrnl
through the upregulation of peroxisome proliferator-activated receptor-γ coactivator-1 (PGC-
1), thereby, suppressing adipocyte dysfunction and insulin resistance [26, 47, 48].
An inverse correlation with serum TG was detected in the subgroup only. We could not
detect any association between serum levels of Metrnl and other parameters of lipid profile,
unlike previous studies [35, 46]. However, this might be explained by the effect of Metrnl treat-
ment in attenuating HFD-induced hypertriglyceridemia in transgenic mice, but not hypercho-
lesterolemia [23].
Interestingly, infertile PCOS patients tended to have lower levels of serum adiponectin,
worse insulin resistance, and higher LH to FSH ratio, as well. On the other hand, PCOS-RPL
patients had higher serum Metrnl, homocysteine, and TG. Nevertheless, they were able to con-
ceive, unlike PCOS-Inf. It can be hypothesized that lower serum levels of Metrnl and adipo-
nectin, and higher levels of homocysteine in patients diagnosed with PCOS, synergistically add
to the ongoing inflammatory process and insulin resistance. Usually, adiponectin performs
anti-inflammatory functions, insulin-sensitizing, and cardioprotective functions [49, 50] by
inhibiting NF-κB pathway in macrophages and dendritic cells [51–53], and is involved in regu-
lating fertility, ovarian functions, and cytotrophoblast invasion [54]. Hypoadiponectinemia
has been associated with CVD [55], increased adiposity, impaired fasting glucose (IFG), insu-
lin resistance, and DM [56], and PCOS [57, 58]. Surprisingly, it has pro-inflammatory function
inducing the release of pro-inflammatory cytokines (such as TNF-α, IL-6, IL-1β) and prosta-
glandins (such as PG2α) in the placenta, by regulating NF-κB and PPAR-γ signaling pathway
[59], in an attempt for an essential degree of inflammation necessary to promote syncytializa-
tion and the invasive capacity of cytotrophoblast. Adiponectin to leptin ratio is diminished in
PCOS [60] and is elevated in those diagnosed with RPL only [61]. Our data showed signifi-
cantly lower adiponectin levels in the PCOS group and subgroups, when compared to controls,
coinciding with the aforementioned. Therefore, both elevated and depressed levels of this adi-
pokine can negatively affect fertility rates in females diagnosed with PCOS with/out RPL,
increasing the risk of insulin resistance and inflammation.
Furthermore, homocysteine is a potent inhibitor of adipogenesis, stimulating AMPK and
suppressing PPAR-γ signaling pathways; and it intensifies the effect of hyperandrogenism on
cardiovascular risk in females diagnosed with PCOS [61]. PCOS group and subgroups had
higher homocysteine levels when compared to control, having a direct association with insulin
resistance [62]. This might be related to the inhibitory effect of homocysteine on adiponectin
biosynthesis by primary adipocytes and PPAR-γ signaling by increasing the methylation of
PPAR-α/γ gene promoter [63], further exacerbating the insulin resistance and inflammation
[64].
The PCOS-Inf and PCOS-RPL females also had significantly higher levels of hs-CRP, an
acute phase reactant primarily produced by IL-6-induced hepatocytes [65]. Numerous studies
demonstrated a correlation between higher serum hs-CRP levels with cardiovascular events in
patients diagnosed with coronary artery disease (CAD), T2DM [66], PCOS [67, 68], and RPL
[69]. However, its use as a “powerful predictor of cardiovascular risk” is still controversial [70];
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while some studies have agreed to this notion [71], a 9-year prospective study concluded that
hs-CRP did not pose any additional effect on conventional risk factors [72]. Nevertheless, in
this study, hs-CRP levels were significantly higher in patients diagnosed with PCOS, also coin-
ciding with previous literature. Furthermore, a strong inverse correlation was detected
between serum Metrnl and hs-CRP levels in the PCOS group and subgroups. The same associ-
ation was detected by Dadmanesh et al. [36], and Li et al. [73], in the context of T2DM and
CAD. El-Ashmawy et al. also found a negative correlation between serum Metrnl and hs-CRP
levels, IL-6, TNF-α, and endothelial dysfunction markers (E-selectin and intracellular adhe-
sion molecule-1) in DM patients. The authors concluded that depressed levels of Metrnl might
“be a stimulus of subclinical inflammation and insulin resistance”, increasing the risk for
developing CVD and DM [42]. These further emphasize that Metrnl protein is involved in the
inflammatory process. Metrnl biosynthesis is induced by an inflammatory stimulus (as by
TNF-α levels), playing a regulatory role in the inflammatory response, upregulating the pro-
duction of anti-inflammatory cytokines (such as IL-4) and abrogating the production of pro-
inflammatory cytokines and chemokines [74]. Metrnl might normally balance the anti-inflam-
matory effect of adiponectin to control the inflammatory response and induce the action of
immunoregulatory immune cells, just enough to create a harboring medium for the approach-
ing fertilized egg. However, in the case of PCOS-Inf, serum levels of Metrnl were not enough
to break the shield of inflammation created by hypoadiponectinemia and hyperhomocysteine-
mia. Therefore, Metrnl protein might have served a protective effect, synergistically with adi-
pokines such as adiponectin, CTRP 12 & 13 [75], against the inflammation and insulin
resistance present in PCOS-RPL group, through PPAR-γ signaling pathway, but was not
enough to maintain viable pregnancy. Future studies might include assessing the expression of
PPAR-γ and its association with Metrnl protein in the pathogenesis of PCOS and RPL to get a
better picture of the underlying mechanisms.
Currently, this is the first study to inquire serum Metrnl protein in females diagnosed with
PCOS and/or RPL. However, there are limitations. First, we could not exclude all potential
bias and confounding factors such as exercise training. Second, in this study, we have used
BMI for assessing body composition based on statistical criterion, and the use of body compo-
sition analysis (dual energy X ray absorptiometry (DEXA) and bioelectrical impedance analy-
sis (BIA)) and functional body composition can give better insight on the possible relation
between serum Metrnl levels and the different tissue masses [44]. Third, additional assessment
of clinical parameters could have been beneficial at drawing more exact conclusions, such
as Ferriman score, and ovarian volume. Fourth, insulin resistance was calculated using
HOMA-IR, instead of the gold standard, the euglycemic/hyperglycemic clamp. Nevertheless,
HOMA-IR remains a universally accepted marker of insulin resistance. Moreover, an addi-
tional group of females affected by RPL but not PCOS could have shed more light on the asso-
ciation of serum Metrnl with the pathogenesis of recurrent miscarriage.
The results of the present study revealed an independent association between Metrnl pro-
tein and PCOS, with a negative correlation with insulin resistance and inflammation. There-
fore, Metrnl might play a role in the pathogenesis of PCOS and recurrent miscarriage.
Nevertheless, the study design limits further conclusion about the consequential relation
between Metrnl and the diseases.
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